Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.8% – What’s Next?

Actuate Therapeutics (NASDAQ:ACTU)’s stock price fell 2.8% during trading on Wednesday . The company traded as low as $8.48 and last traded at $8.69. 35,969 shares were traded during trading, a decline of 12% from the average session volume of 40,781 shares. The stock had previously closed at $8.94.

Actuate Therapeutics Trading Down 1.4 %

The stock has a 50 day moving average price of $7.70.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Tuesday, September 24th. The company reported ($4.20) EPS for the quarter.

Insider Transactions at Actuate Therapeutics

In other Actuate Therapeutics news, major shareholder Leslie W. Kreis sold 24,999 shares of Actuate Therapeutics stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total value of $224,991.00. Following the transaction, the insider now owns 131,248 shares in the company, valued at $1,181,232. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Todd S. Thomson sold 18,750 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $8.00, for a total value of $150,000.00. Following the completion of the transaction, the insider now owns 1,184,795 shares of the company’s stock, valued at $9,478,360. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Leslie W. Kreis sold 24,999 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the transaction, the insider now owns 131,248 shares of the company’s stock, valued at approximately $1,181,232. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Trading of Actuate Therapeutics

An institutional investor recently bought a new position in Actuate Therapeutics stock. KG&L Capital Management LLC purchased a new stake in Actuate Therapeutics (NASDAQ:ACTU) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned 0.06% of Actuate Therapeutics at the end of the most recent quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.